

AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph beginning on page 1, starting at line 4, and ending on page 1, line 15, with the following paragraph:

This application is filed as a divisional of U.S. Application No. 08/319,506, filed October 6, 1994, which is a continuation of U.S. Application No. 07/850,675, filed March 13, 1992, which is a continuation-in-part of (1) United States Patent Application Serial No. 07/822,296, filed January 17, 1992 entitled Method for Treating Tumor Necrosis Factor Mediated Diseases, (2) United States Patent Application Serial No. 07/669,862, filed March 15, 1991 entitled Site Specific Pegylation of Polypeptides, (3) United States Patent Application Serial No. 07/506,522, filed April 6, 1990 entitled Interleukin-1 Inhibitors, which is a continuation of United States Patent Application Serial No. 07/266,531, filed November 3, 1988, which is a continuation-in-part of United States Patent Application Serial No. 07/248,521, filed September 23, 1988, which is a continuation-in-part of United States Patent Application Serial No. 07/238,713, filed August 31, 1988, which is a continuation-in-part of United States Patent Application Serial No. 07/199,915, filed May 27, 1988; and (4) United States Patent Application Serial No. 07/555,274 filed July 19, 1990 entitled Tumor Necrosis Factor (TNF) Inhibitor and Method for Obtaining Same.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com